A View LCS vs EchoNext

Similar category, different focus. These tools serve overlapping but distinct needs. Comparability 65/100 Comparability is an AI-graded 0–100 score of how directly these two tools compete — higher means a more apples-to-apples comparison.

A View LCS

by Coreline Soft Co.

EchoNext

by Pathway Labs

AI Verdict

Both tools are FDA-cleared AI solutions in cardiology, but they differ significantly in their diagnostic approach. AVIEW LCS analyzes CT scans for a broad range of thoracic conditions including cardiac calcification, while EchoNext focuses on ECG analysis to detect hidden structural heart disease. Therefore, AVIEW LCS is suitable for detailed imaging-based thoracic assessment, whereas EchoNext is designed for early detection of cardiac conditions via ECGs.

Choose A View LCS if…

Choose A View LCS if your primary need is comprehensive thoracic CT analysis, particularly for lung cancer screening programs. This tool excels at automated lung nodule detection, classification, and volume quantification, along with emphysema and coronary artery calcification analysis from a single low-dose CT scan. It's ideal for radiology departments and pulmonology practices focused on early detection and detailed assessment of multiple thoracic conditions.

View A View LCS →

Choose EchoNext if…

Choose EchoNext if you need an efficient, non-invasive screening tool to detect hidden structural heart disease from standard ECGs. This AI-powered solution is best suited for broad access settings, from hospitals to community practices, aiming to identify patients at risk for conditions like heart failure, valve disease, and pulmonary hypertension who may otherwise be missed. It can help bridge the gap between routine ECGs and the need for further echocardiogram evaluation.

View EchoNext →

Reviewed by Pouyan Golshani, MD — Interventional Radiologist

Quick Comparison

Feature	A View LCS	EchoNext
Pricing	Contact for quote	Starts at $600/month
Deployment	Cloud-based, Hybrid solution, Locally on dedicated hardware, Locally virtualized (virtual machine, Docker)	Available through the OpenEvidence clinical decision support platform.
BAA Available	Unknown	Yes AI-estimated
FDA Status	1 AI-estimated	Yes AI-estimated
HIPAA	Unknown	Yes AI-estimated

Head-to-Head

AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.

Usability

A View LCS

AVIEW LCS emphasizes a user-friendly viewer with advanced 3D rendering of patient lungs, making abnormal findings more intuitive and easier to explain to both medical professionals and patients. It also highlights automated report generation to save time and streamline tasks. While EchoNext is integrated into the OpenEvidence platform, its specific usability features beyond integration are not detailed.

Clinical Value

EchoNext

EchoNext has demonstrated superior accuracy in detecting structural heart disease from ECGs compared to cardiologists, even those assisted by AI. It has also been credited with leading to the first peer-reviewed case of a heart transplant attributable to AI-based disease detection. AVIEW LCS has shown lower likelihood of misidentifying large nodules compared to human radiologists and can reduce radiologist workload, but its comparative diagnostic accuracy against human experts isn't as strongly highlighted for its primary indications.

Pricing & Value

EchoNext

EchoNext offers transparent tiered pricing starting at $600/month, with details on implementation fees and annual discounts. AVIEW LCS only states 'contact for quote,' which offers less transparency. EchoNext's ability to screen for multiple structural heart diseases from a routine, inexpensive ECG also suggests significant value by potentially reducing the need for more costly follow-up imaging.

Enterprise Readiness

A View LCS

AVIEW LCS offers multiple deployment options including cloud-based, hybrid, and local installations, providing flexibility for various enterprise IT infrastructures. It also supports standardized reporting (Lung-RADS, EUPS, K-lung-RADS) and seamless integration with major PACS systems. EchoNext is available through the OpenEvidence platform, which has broad reach, but its direct deployment flexibility for enterprises is less detailed.

Innovation

EchoNext

EchoNext is highlighted as the world's first FDA-approved AI detection tool to analyze standard ECGs for hidden structural heart disease across six indications. This represents a novel approach to early detection for a leading cause of death. AVIEW LCS is innovative in its comprehensive thoracic CT analysis, but EchoNext's application to a widely available and inexpensive test like the ECG for such a broad range of conditions is a more significant paradigm shift.

Support & Docs

Tie

Both tools are FDA-cleared and have numerous clinical validation studies and publications supporting their efficacy. AVIEW LCS has over 290 peer-reviewed publications and is used in 7 national lung cancer screening programs. EchoNext has also been extensively validated with large datasets and published in prominent journals like Nature Medicine. However, specific details on ongoing customer support, training, or documentation beyond these validations are not provided for either tool.

Feature-by-Feature

Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.

Feature	A View LCS	EchoNext
Tool Name	A View LCS	EchoNext
Company	Coreline Soft Co.	Pathway Labs
Description	AVIEW LCS by Coreline Soft is an FDA-cleared AI-powered medical imaging platform for comprehensive thoracic CT analysis, specializing in lung cancer screening, emphysema quantification, and coronary artery calcification detection from a single low-dose CT scan.	EchoNext is an FDA-cleared AI tool from Pathway Labs that analyzes standard ECGs to detect hidden structural heart disease, including heart failure, valve disease, and pulmonary hypertension.
Key Features (Cardiology)	Coronary Artery Calcium (CAC) scoring (Agatston, volume, mass), Segmentation of major coronary arteries	AI-powered ECG analysis, Detection of hidden structural heart disease, Identifies heart failure risk, Screens for valve disease, Detects pulmonary hypertension indicators, Utilizes standard 12-lead ECGs
Key Features (Pulmonology/Thoracic)	Automated lung nodule detection and classification, Nodule volume quantification and measurement (3D), Lung-RADS scoring and reporting, Emphysema analysis and quantification (LAA), Automated comprehensive report generation (PDF, DICOM PDF, SR), CT kernel conversion AI technology	Not specified
Specialties	Cardiology, Pulmonology, Radiology	Cardiology, Family Medicine, Hospital Medicine, Internal Medicine

Videos

Demos, reviews, and walkthroughs featuring A View LCS and EchoNext.

Loading videos…

Videos need JavaScript to load. Search YouTube directly →

View all on YouTube

Frequently Asked Questions

How deeply can each tool integrate into existing EHR and PACS systems to streamline workflow?

AVIEW LCS supports standard DICOM connectivity and integrates with existing PACS and RIS environments, offering standalone workstation operation or embedding within third-party platforms like Bayer's Calantic Medical Imaging and INFINITT PACS. EchoNext integrates with the OpenEvidence clinical decision support platform, which serves over 500,000 physicians, aiming to put its screening output directly into existing physician workflows at the point of care.

What is the reported accuracy and sensitivity of each tool in detecting relevant clinical conditions?

AVIEW LCS has demonstrated high detection sensitivity (u2265 83%) for pulmonary nodules and a reported sensitivity of 97% and specificity of 76% in clinical trials for lung nodule detection. EchoNext achieved an AUROC of 85.2% in internal tests and 78-80% in external validation for detecting structural heart disease, outperforming cardiologists in a study with 77% accuracy compared to 64% for cardiologists alone.

For which specific specialties are these tools best suited, and what clinical context do they address?

AVIEW LCS is best suited for Radiology, Pulmonology, and Cardiology, providing comprehensive thoracic CT analysis for lung cancer screening, emphysema quantification, and coronary artery calcification. EchoNext is designed for Cardiology, Family Medicine, Hospital Medicine, and Internal Medicine, focusing on detecting hidden structural heart disease, including heart failure, valve disease, and pulmonary hypertension, from standard ECGs.

What is the typical learning curve for physicians to effectively use each tool in their practice?

AVIEW LCS aims to optimize reading time and increase accuracy, with clinical validation showing radiologists using AVIEW 2.0 achieved an 89% increase in case throughput and a 60% reduction in interpretation time. EchoNext is designed to be a screening tool that analyzes ECG data to identify patients who should be evaluated for structural heart disease, suggesting it provides clear indications for further action.

What audit-trail features are available to ensure transparency and accountability in the use of these AI tools?

AVIEW LCS produces standardized nodule analysis outputs that support structured reporting workflows, which can be incorporated into institutional reporting templates for documentation. While specific audit-trail features for EchoNext are not detailed, general AI security best practices for sensitive data include continuous posture monitoring, role-based access control, and logging access to align with audit requirements.

What considerations are important for rolling out these tools across multiple clinical sites or a large healthcare system?

AVIEW LCS is built for multi-site operations, applying the same detection algorithms and measurement protocols across all sites to ensure standardized quality. Coreline Soft offers flexible licensing models and dedicated onboarding support for multi-site deployments. EchoNext is designed for broad access, from major hospitals to community practices, and its partnership with OpenEvidence aims to facilitate widespread availability.